Hyoscyamine

Hyoscyamine is used to control symptoms associated with disorders of the gastrointestinal (GI) tract. It is indicated for use in the treatment of bladder spasms, peptic ulcer disease, diverticulitis, colic, irritable bowel syndrome, cystitis, and pancreatitis. Hyoscyamine can also be used to treat certain heart conditions, to control the symptoms of Parkinson’s disease, rhinitis, and to reduce excess saliva production. Hyoscyamine is an isomer of atropine and is also known as levo-atropine. It exhibits anticholinergic activity and functions as a non-selective, competitive antagonist of muscarinic receptors, inhibiting the parasympathetic activities of acetylcholine on the salivary, bronchial, and sweat glands as well as in the eye, heart, and GI tract. The actions of hyoscyamine result in a reduction in salivary, bronchial, gastric, and sweat gland secretions, mydriasis, cycloplegia, change in heart rate, contraction of the bladder detrusor and GI smooth muscles, and decreased GI motility.

Affygility Solutions has an occupational exposure limit (OEL) and control band assignment for this active pharmaceutical ingredient (API). This monograph also contains the acceptable daily exposure (ADE) value.

Hyoscyamine

CAS Registry Number:
101-31-5
Trade names:
ED-Spaz®, Levsin®, Cystospaz ®, Hyomax®, Hyophen®, Hyosyne®, Oscimin®
Cost:
$639 USD

ADD TO CART

Why do you need this OEL Fastrac monograph?

OEL Fastrac monographs are a cost-effective and convenient way to meet the requirements for PDEs (ADEs) contained in the EMA Guideline on setting health based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities (EMA/CHMP/CVMP/SWP/169430/2012), and to obtain the following information:

  • The numerical OEL and control band assignment needed to determine the level of required engineering controls and personal protective equipment
  • A listing of all cited references utilized in the derivation of the OEL and ADE
  • An expert review and discussion with respect to the critical endpoints of concern, the rationale for the choice of endpoints, and dose that is to be used in the derivation of the ADE (PDE), as required by the EMA's Guideline on setting health-based exposure limits for use in risk identification in the manufacture of different medicinal products in shared facilities

Benefits of OEL Fastrac monographs

  • Fully documented. 10-12 pages in length, with calculations and cited references.
  • Save time! Unsurpassed delivery with instant download.
  • Save money. Similar documents cost 5-12 times as much.
  • Stay current. Automatic notification of revisions.

How to order

To order an OEL monograph for this compound, just click the ADD TO CART button.

HBEL

If you're wondering about HBEL, we have something for you.

Search OEL Fastrac

Not the compound you were looking for? You can search the OEL Fastrac catalog to find more available compounds.

Affygility Solutions’s OEL Fastrac service is an user-friendly system that enables us to make confident decisions and focus on moving the compound safely through our facility. We can quickly access the database to determine if a new drug is within the OEL Fastrac library, and if so, immediately download a detailed OEL banding report. The OEL Fastrac system has been a helpful tool in our overall EH&S program.
  • K. Rosenthal
  • Director of Manufacturing
  • Pharmatek Laboratories